TP53 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), bergapten has been shown to induce G1 arrest associated with p53-mediated signaling, and network pharmacology combined with molecular docking further elucidated its interaction with multiple targets involved in NSCLC progression [140].